Wegovy and a High Heart Rate: What You Should Know

You notice your heart beating faster than usual — here is why that happens

Picture the scenario: a few weeks into Wegovy, you sit down in the evening and notice your heart feels quicker than normal. You have not exercised. You are not anxious. It is simply there, a slightly elevated resting pulse. This is one of the more commonly reported cardiovascular side effects of semaglutide, and it has a physiological explanation.

GLP-1 receptor agonists like semaglutide act on receptors throughout the body, not only in the gut. The heart and autonomic nervous system carry GLP-1 receptors too. Stimulating them can nudge the sympathetic nervous system, which in turn raises heart rate. The increase observed in the STEP clinical trials was modest (averaging around 1 to 5 beats per minute above baseline) and the NHS semaglutide medicines page lists a fast or irregular heartbeat among the possible side effects you may notice.

For most people this matters very little. A resting heart rate that creeps from 68 to 72 beats per minute is clinically unremarkable. The effect tends to peak early, often within the first month at a new dose, and then settle as your system adjusts. If you have been tracking your pulse on a smartwatch, a small upward shift in those early weeks is unlikely to mean anything serious, but that does not mean every instance of a raised heart rate can be dismissed.

There is a fuller discussion of the mechanisms behind semaglutide and heart rate if you want to understand the pharmacology in more depth.

When a faster pulse crosses the line from side effect to symptom

The distinction that matters most is between an incidental rise in resting rate and something that feels clinically significant. A few markers are worth keeping in mind.

If your heart rate sits consistently above 100 beats per minute at rest (known as tachycardia) that deserves a conversation with a healthcare professional, not because Wegovy is necessarily the cause, but because it needs explaining. Equally, if you feel palpitations that are rapid, irregular or accompanied by chest tightness, shortness of breath, lightheadedness or near-fainting, you should seek medical assessment promptly. Those symptoms together can reflect something unrelated to weight-loss treatment that happens to have appeared at the same time.

The MHRA's guidance on GLP-1 medicines notes that patients on these treatments should be aware of cardiovascular symptoms and report anything unexpected. You can find information on reporting via the MHRA Yellow Card scheme, which covers both side effects and concerns about the medicine itself. Your prescriber can also review whether continuing at your current dose makes sense, or whether a slower titration would reduce the cardiovascular load while your body adjusts.

If you are curious about the broader question of how Wegovy affects heart rate across different doses, that page covers the dose-dependent picture in more detail.

What a prescriber will want to know, and how nume reviews this

When a patient raises a heart-rate concern, a prescriber's first questions are predictable: how fast, how long, any other symptoms, any pre-existing cardiac history? Those answers shape whether the response is reassurance, a brief pause in titration, or a referral to the GP for an ECG.

One practical point: if you notice the palpitations tend to coincide with the 24 hours after your injection rather than persisting all week, that pattern is consistent with the peak drug-concentration window and is useful information to share. Noting it down when it happens (maybe as a quick note on your phone before you head to bed) gives your prescriber something concrete to work with rather than a vague recollection.

At nume, every patient's situation is reviewed by a GPhC-registered Independent Prescriber, not by a software system, and that access does not stop once your first pen arrives. The aftercare team is available seven days a week, so questions about side effects like a raised heart rate have somewhere to go. A real clinician reads your concern the same day. If you are considering starting treatment and want to understand how the review process works, our frequently asked questions cover the consultation in detail.

It is also worth reading about Wegovy and heart rate from an evidence angle if you want to see how the clinical trial data breaks this down by dose and duration.

Context that matters: semaglutide's overall cardiac picture

Placing a modest rise in resting heart rate alongside the wider cardiovascular evidence is genuinely helpful here. The SELECT trial demonstrated that semaglutide at the 2.4mg dose reduced the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with obesity and established cardiovascular disease. That is a substantial benefit on one hand; a small average increase in resting pulse on the other. For the vast majority of people, the net cardiovascular picture is positive, not neutral, and certainly not negative.

That said, if you already have a diagnosed cardiac arrhythmia or you are taking medicines that affect your heart rate, your prescriber needs to know before you start. If you are wondering whether Wegovy can cause a high heart rate, that page looks at the evidence and explains which patient groups warrant closer monitoring. For a wider overview of how Wegovy works and who it is suitable for, our Wegovy treatment page covers eligibility, the dosing schedule and what the consultation involves. If cost is on your mind at the same time, our Wegovy pricing page explains what is included in a private prescription and why the fee covers more than the pen itself.